Viibryd
Developed for major depression, intended to target serotonin pathways to alleviate depressive symptoms and support emotional stability.
Strengths: 20 · 40mg
Where to Check Availability
Medicine details
- Conditions
- Therapeutic class
Selective Serotonin Reuptake Inhibitor (SSRI)
- Pharmacological class
SSRI
- Contraindications
concurrent use of MAO inhibitors
- Precautions and warnings
monitor for suicidal ideation; avoid abrupt discontinuation
- Minor side effects
nausea; diarrhoea
- Moderate side effects
dizziness; insomnia; fatigue
- Serious side effects
serotonin syndrome — requires immediate medical attention
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
AbbVie
- Onset Time
1–2 weeks
- Duration
24 hours
- Storage instructions
Store at room temperature in a dry place.
- Drug interactions
MAO inhibitors; triptans; aspirin
- Age restrictions
Use with caution in young adults.
- Pregnancy and breastfeeding
Pregnancy: Use only if necessary. Breastfeeding: Caution advised.
Patient summary
Developed for major depression, intended to target serotonin pathways to alleviate depressive symptoms and support emotional stability.
Mechanism of action
Vilazodone acts as an SSRI and a 5-HT1A receptor partial agonist. It inhibits the reuptake of serotonin, increasing its availability in the synaptic cleft, which helps enhance neurotransmission associated with mood regulation.
Viibryd
Developed for major depression, intended to target serotonin pathways to alleviate depressive symptoms and support emotional stability.
Editorial Notes
- Active ingredient(s): Vilazodone
- Listed indication(s): Major Depressive Disorder
Usually available as
- 90 tablets - 20 mg1534-20-mg-18053
- 60 tablets - 40 mg1534-40-mg-18057